CN1518597A - 新的成纤维细胞生长因子 - Google Patents

新的成纤维细胞生长因子 Download PDF

Info

Publication number
CN1518597A
CN1518597A CNA018202993A CN01820299A CN1518597A CN 1518597 A CN1518597 A CN 1518597A CN A018202993 A CNA018202993 A CN A018202993A CN 01820299 A CN01820299 A CN 01820299A CN 1518597 A CN1518597 A CN 1518597A
Authority
CN
China
Prior art keywords
fgf
polypeptide
nucleotide sequence
sequence
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018202993A
Other languages
English (en)
Chinese (zh)
Inventor
�˵á�W�����ָ���
彼得·W·布林格曼
达里·福尔兹
ά
布拉尼斯拉娃·米特罗维奇
��ɣ��˹��������
苏巴·斯里尼瓦桑
Ŭ
詹姆斯·奥努佛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of CN1518597A publication Critical patent/CN1518597A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA018202993A 2000-12-08 2001-12-10 新的成纤维细胞生长因子 Pending CN1518597A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25183700P 2000-12-08 2000-12-08
US60/251,837 2000-12-08
US10/005,646 2001-12-07
US10/005,646 US20020151496A1 (en) 2000-12-08 2001-12-07 Novel fibroblast growth factors

Publications (1)

Publication Number Publication Date
CN1518597A true CN1518597A (zh) 2004-08-04

Family

ID=26674594

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018202993A Pending CN1518597A (zh) 2000-12-08 2001-12-10 新的成纤维细胞生长因子

Country Status (21)

Country Link
US (2) US20020151496A1 (https=)
EP (1) EP1389237A2 (https=)
JP (1) JP2005506275A (https=)
KR (1) KR20040052442A (https=)
CN (1) CN1518597A (https=)
AU (1) AU2603402A (https=)
BG (1) BG107888A (https=)
BR (1) BR0116507A (https=)
CA (1) CA2431374A1 (https=)
CZ (1) CZ20031570A3 (https=)
EE (1) EE200300269A (https=)
HU (1) HUP0400657A1 (https=)
IL (1) IL156259A0 (https=)
MX (1) MXPA03005142A (https=)
NO (1) NO20032573L (https=)
PL (1) PL366158A1 (https=)
RU (1) RU2329058C2 (https=)
SI (1) SI21372A (https=)
SK (1) SK7012003A3 (https=)
WO (1) WO2002046424A2 (https=)
ZA (1) ZA200305236B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107050428A (zh) * 2017-03-23 2017-08-18 温州医科大学 Fgf20药物及其对脑创伤的治疗应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US20050176631A1 (en) * 2002-01-15 2005-08-11 Heuer Josef G. Method for reducing morbidity and mortality in critically ill patients
EP1608411B1 (en) 2003-04-01 2010-09-29 United States Government as represented by the Department of Veteran's Affaires Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure.
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
CN105601748B (zh) 2011-07-01 2021-08-27 恩格姆生物制药公司 用于代谢病症和疾病治疗的组合物、应用和方法
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
ES2915851T3 (es) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
CA2927592C (en) 2013-10-28 2020-08-18 Ngm Biopharmaceuticals, Inc. Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
RU2729161C2 (ru) 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
AU3924300A (en) * 1999-04-02 2000-10-23 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
AU1101901A (en) * 1999-10-22 2001-05-08 Chiron Corporation Human fgf-20 gene and gene expression products
EP2163626A1 (en) * 1999-11-18 2010-03-17 Novartis Vaccines and Diagnostics, Inc. Human FGF-21 gene and gene expression products
AU2001262934A1 (en) * 2000-06-01 2001-12-11 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
AU7181101A (en) * 2000-07-03 2002-01-14 Curagen Corp Novel fibroblast growth factors and nucleic acids encoding same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107050428A (zh) * 2017-03-23 2017-08-18 温州医科大学 Fgf20药物及其对脑创伤的治疗应用
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用

Also Published As

Publication number Publication date
BG107888A (bg) 2004-08-31
ZA200305236B (en) 2005-06-29
IL156259A0 (en) 2004-01-04
NO20032573L (no) 2003-07-22
SI21372A (sl) 2004-06-30
CZ20031570A3 (cs) 2004-01-14
RU2003119657A (ru) 2005-02-27
AU2002226034A2 (en) 2002-06-18
CA2431374A1 (en) 2002-06-13
BR0116507A (pt) 2004-01-06
MXPA03005142A (es) 2004-10-15
WO2002046424A3 (en) 2003-11-27
RU2329058C2 (ru) 2008-07-20
AU2603402A (en) 2002-06-18
EE200300269A (et) 2003-10-15
JP2005506275A (ja) 2005-03-03
EP1389237A2 (en) 2004-02-18
US20080057076A1 (en) 2008-03-06
WO2002046424A2 (en) 2002-06-13
SK7012003A3 (en) 2004-04-06
HUP0400657A1 (en) 2006-04-28
KR20040052442A (ko) 2004-06-23
NO20032573D0 (no) 2003-06-06
PL366158A1 (en) 2005-01-24
US20020151496A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
US20080057076A1 (en) Novel fibroblast growth factors
DK2055308T3 (en) PHARMACEUTICALS FOR PROMOTING FUNCTIONAL REGENERATION OF DAMAGED TISSUE
US7671180B2 (en) Fibroblast growth factor-like polypeptides and variants thereof
EP1257645A2 (en) Fibroblast growth factor-23 molecules and uses thereof
JP2006507804A (ja) 単一ドメインｔｄｆ関連化合物およびその類似体
HK1068648A (en) Novel fibroblast growth factors
AU2002226034B2 (en) Fibroblast growth factors
JP2004504042A (ja) グリコシル化ｖｅｇｆ−ｂ及び可溶性ｖｅｇｆ−ｂの量を増加させるための方法
WO1998017798A1 (en) Placental-derived prostate growth factors
JP2003510051A (ja) Ｍａｐキナーゼ経路を活性化するホスファターゼ
AU2007203341A1 (en) Fibroblast growth factors
CN1186515A (zh) 转化生长因子αHI
AU2002226034A1 (en) Fibroblast growth factors
US20020127594A1 (en) Don-1 gene and polypeptides and uses therefor
CN1414021A (zh) 成纤维细胞生长因子13的抗体、拮抗剂及激动剂
HK1008485A1 (en) Vascular endothelial growth factor-b
HK1008485B (en) Vascular endothelial growth factor-b
HK1144437A (en) Fibroblast growth factor-like polypeptides
CN1343688A (zh) 人nip2相关蛋白和编码序列及其用途
JPWO2000071581A1 (ja) 新規ポリペプチド

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1068648

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1068648

Country of ref document: HK